Natco Pharma Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Pomalidomide Capsules, a thalidomide analogue, are indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

The drug is also approved for AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy (HAART), as well as for HIV-negative adult patients with Kaposi sarcoma. The product is available in 1 mg, 2 mg, 3 mg, and 4 mg strengths and is primarily distributed through specialty pharmacies and clinics.

NATCO said based on information made available by the U.S. Food and Drug Administration (FDA), it believes that it has 180 days of shared exclusivity. Pomalidomide Capsules 1 mg, 2 mg, 3 mg, and 4 mg had estimated sales of $3.2 billion in the U.S. for the 12 months ending September 2025, the company said, citing industry sales data.

Rajeev Nannapaneni, vice chairman and chief executive officer of NATCO Pharma, said, ?We are pleased to launch Pomalidomide Capsules in the U.S.; this further strengthens our oncology and specialty portfolio in the U.S. The launch highlights our commitment to our mission of making specialty medicines accessible to all the patients worldwide. We look forward to bringing more such complex and specialty products to the market in the coming years.?

NATCO Pharma, headquartered in Hyderabad, India, develops, manufactures, and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients, and crop protection products.

The company?s consolidated net profit jumped 13.9% to Rs 151.50 crore on a 36.3% increase in revenue from operations to Rs 647.30 crore in Q3 FY26 over Q3 FY25.

Powered by Capital Market - Live News

Akums Drugs & Pharmaceuticals Ltd, RHI Magnesita India Ltd, Brainbees Solutions Ltd, Inox Wind Ltd are among the other stocks to see a surge in volumes on NSE today, 16 February 2026.

Natco Pharma Ltd witnessed volume of 188.67 lakh shares by 14:14 IST on NSE, a 30.19 times surge over two-week average daily volume of 6.25 lakh shares. The stock increased 9.68% to Rs.903.60. Volumes stood at 4.52 lakh shares in the last session.

Akums Drugs & Pharmaceuticals Ltd registered volume of 22.18 lakh shares by 14:14 IST on NSE, a 21.84 fold spurt over two-week average daily volume of 1.02 lakh shares. The stock rose 6.35% to Rs.480.00. Volumes stood at 70716 shares in the last session.

RHI Magnesita India Ltd registered volume of 13.51 lakh shares by 14:14 IST on NSE, a 9.47 fold spurt over two-week average daily volume of 1.43 lakh shares. The stock rose 4.88% to Rs.457.95. Volumes stood at 1.13 lakh shares in the last session.

Brainbees Solutions Ltd clocked volume of 77.54 lakh shares by 14:14 IST on NSE, a 7.68 times surge over two-week average daily volume of 10.10 lakh shares. The stock lost 10.49% to Rs.241.50. Volumes stood at 10.2 lakh shares in the last session.

Inox Wind Ltd notched up volume of 456.78 lakh shares by 14:14 IST on NSE, a 6.18 fold spurt over two-week average daily volume of 73.91 lakh shares. The stock slipped 3.03% to Rs.103.16. Volumes stood at 78.58 lakh shares in the last session.

Powered by Capital Market - Live News

Natco Pharma received approval for Semaglutide from Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic Semaglutide Injection in India. NATCO will launch the product in the India market in March'26.

Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

Powered by Capital Market - Live News

NATCO Pharma announced that the U.S. Food and Drug Administration (FDA) had conducted an inspection at the Active Pharmaceutical Ingredient Division located in Manali, Chennai from 17 November - 21 November 2025. The Company received seven (7) observation in the Form-483.

Further, the Company has received the EIR (Establishment Inspection Report) from the USFDA on the classification of the above-referred inspection as Voluntary Action Indicated (VAI).

Powered by Capital Market - Live News